Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Rocepafant (Alias: LAU-8080, LAU8080, LAU 8080, BN-50730, BN50730, BN 50730)

Catalog No. T28607 Copy Product Info
Purity: 98.95%
😃Good
Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.

Rocepafant

Copy Product Info
😃Good
Catalog No. T28607
Alias LAU-8080, LAU8080, LAU 8080, BN-50730, BN50730, BN 50730

Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.

Rocepafant
Cas No. 132579-32-9
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$46In StockIn Stock
5 mg$106In StockIn Stock
10 mg$156In StockIn Stock
25 mg$303In StockIn Stock
50 mg$413In StockIn Stock
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
Custom-made molecule. TargetMol’s expert synthesis team delivers cost-effective solutions. Contact us for inquiries. Committed to serving you.
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.95%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.
Targets&IC50
PAF receptor:0.74 nM
In vivo
Ten patients with active disease were treated for 4 weeks with a PAF receptor antagonist, Rocepafant, given orally (40 mg twice daily). The treatment period was followed by a 4-week follow-up period. Clinical indicators of disease activity significantly improved during the treatment period, with a progressive return to baseline values during the follow-up period. No significant change in laboratory variables was observed. The tolerance of the treatment was excellent, and no clinical or laboratory evidence of side effects was recorded. These results must be confirmed in a controlled study, but suggest an anti-inflammatory effect.[4]
SynonymsLAU-8080, LAU8080, LAU 8080, BN-50730, BN50730, BN 50730
Chemical Properties
Molecular Weight535.08
FormulaC26H23ClN6OS2
Cas No.132579-32-9
SmilesCC=1N2C3=C(C4=C(S3)CN(C(NC5=CC=C(OC)C=C5)=S)CC4)C(=NCC2=NN1)C6=C(Cl)C=CC=C6
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 55 mg/mL (102.79 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.8689 mL9.3444 mL18.6888 mL93.4440 mL
5 mM0.3738 mL1.8689 mL3.7378 mL18.6888 mL
10 mM0.1869 mL0.9344 mL1.8689 mL9.3444 mL
20 mM0.0934 mL0.4672 mL0.9344 mL4.6722 mL
50 mM0.0374 mL0.1869 mL0.3738 mL1.8689 mL
100 mM0.0187 mL0.0934 mL0.1869 mL0.9344 mL
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Rocepafant | purchase Rocepafant | Rocepafant cost | order Rocepafant | Rocepafant chemical structure | Rocepafant in vivo | Rocepafant formula | Rocepafant molecular weight